Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CTX-944** is a proprietary live biotherapeutic product (microbial therapeutic) developed by ConsortiaTX for the treatment of food allergies. It is designed as a first-in-kind, allergen-independent therapy that leverages microbiome modulation to reverse allergic responses, building on research into microbial consortia that promote immune tolerance to allergens. The therapy aims to reprogram the gut microbiome to induce desensitization and long-term tolerance, potentially addressing peanut and other food allergies without relying on specific allergen exposure.[3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CTX-944.